Revive Therapeutics Ltd. · CSE:RVV
Revive Therapeutics — Investor Presentation (May 2024)
16 slides from Revive Therapeutics's investor presentation, May 2024
Slide 1: A Specialty Life Sciences Company – Corporate Presentation
A SPECIALTY LIFE SCIENCES COMPANY Corporate Presentation May 2024 OTCQB: FRANKFURT: RVVTF 31R Revive Therapeutics Ltd. | Office: 1-888-901-0036 | E-mail: info@revivethera.com
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward- looking information may relate to our future outlook and anticipated events or results and may include statements regarding our future f
Slide 3: Revive Therapeutics
REVIVE THERAPEUTICS Bucillamine Focused on the development Advancing novel use of of therapeutics and Bucillamine for Long COVID diagnostics for infectious and companion diagnostic, LONG COVID DIAGNOSTIC diseases, bioweapons and and medical countermeasures substance abuse Psilocybin Robust patent po
Slide 4: Strategy
STRATEGY Clinical development Target Markets Intellectual Property FDA Designations • Bucillamine and • Infectious Diseases • Novel Uses • Orphan Drug diagnostic for Long COVID • Mental Health • Formulations • Fast Track • Bucillamine for Nerve • Rare Disorders • Delivery Systems • Breakthrough Agen
Slide 5: Intellectual Property Portfolio
INTELLECTUAL PROPERTY PORTFOLIO Title Patent Appln. No. 62/991,996, PCT/CA2021/050350, CAD 3,172,170, US 17/912,597, Japan 2022- Use of Bucillamine in the Treatment of Infectious Diseases, including COVID-19 556099, EP21772039.0, South Korea 10-2022-7036230, Hong Kong 62023075486.8 Use of Bucillamin
Slide 6: Product Pipeline
PRODUCT PIPELINE Focus on Infectious Diseases, Medial Countermeasures, Substance Abuse Product Indication Stage of Development Regulatory Status Bucillamine Infectious Diseases Determining next steps Completed Phase 3 (Oral Tablet) COVID-19 and international opps Bucillamine Infectious Diseases Phas
Slide 7: Infectious Disease Opportunity
INFECTIOUS DISEASE OPPORTUNITY Bucillamine potential for Bucillamine Revive’s clinical history Bucillamine scientific COVID-19 Safety Profile with Bucillamine rationale as an intervention for COVID-19 (see Appendix) • Potential treatment for reduction in • Well-known safety profile and prescribed •
Slide 8: Long COVID Opportunity
LONG COVID OPPORTUNITY © COPYRIGHT 2024. Revive Therapeutics Ltd. ALL RIGHTS RESERVED.
Slide 9: Psychedelics Programs
PSYCHEDELICS PROGRAMS Psilocybin for Substance Abuse Disorders Program • Collaboration with University of Wisconsin-Madison for the clinical development of Methamphetamine use disorder Novel Psilocybin Biosynthesis Enzymatic Platform • Collaboration with NCSU, under Dr. Gavin Williams, to develop a
Slide 10: Formulation & Delivery Technology
FORMULATION & DELIVERY TECHNOLOGY Delivering naturally extracted and synthetic psychedelics DELIVERY SYSTEM Combines Tannin (antibacterial, antifungal, antioxidant, wound healing) and Chitosan (blood-clotting and antimicrobial) composites Releases (rapid, controlled, sustained), improved bioavailabi
Slide 11: Strategic Partners
STRATEGIC PARTNERS Bucillamine Bucillamine Long COVID Rapid Test Formulation Chemical Warfare Clinical Research Psilocybin Biosynthesis Psilocybin © COPYRIGHT 2024. Revive Therapeutics Ltd. ALL RIGHTS RESERVED.
Slide 12: Expected Milestones
EXPECTED MILESTONES H1 2024 • FDA meeting for Bucillamine to • Interim-results of Phase 1/2 study treat LONG COVID for Psilocybin (Methamphetamine Use Disorder) at University of • FDA meeting for LONG COVID Wisconsin Lab and Rapid Test diagnostic development • Complete reformulation of Bucillamine I
Slide 13: Team
TEAM Management Clinical & Regulatory Board of Directors • Michael Frank • Dr. Kelly McKee, Jr., MD, MPH • Michael Frank Chairman and CEO Chief Scientific Officer, Consultant Chairman and CEO • Carmelo Marrelli • Dr. Arshi Kizilbash, M.D. • William Jackson Chief Financial Officer Medical Advisor, Co
Slide 14: Stock Information
STOCK INFORMATION Ticker 52-Week High/Low Market Cap R V V (CSE) | R V V T F (OTCQB) | 31R (Frankfurt) CAD $0.08 / $0.02 CAD ~ $10,500,000 Share Price Capital Structure CAD $0.025 (May 16, 2024) 418,564,269 common shares 35,320,334 stock options 63,317,263 warrants ($0.05 - $0.20) © COPYRIGHT 2024.
Slide 15: Appendix – Bucillamine Scientific Rationale for COVID-19
APPENDIX – BUCILLAMINE SCIENTIFIC RATIONALE FOR COVID-19 Current antiviral interventions for influenza have exhibited modest efficacy, especially in improving mortality in at-risk populations, such as the elderly.1,2 Novel antivirals have been plagued by poor oral bioavailability and lack of efficac
Slide 16: Appendix – Bucillamine Scientific Rationale for COVID-19 (References)
APPENDIX – BUCILLAMINE SCIENTIFIC RATIONALE FOR COVID-19 References 1. Muthuri SG, Venkatesan S, Myles PR et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
Revive Therapeutics — Investor Presentation (May 2024) on 6ix